{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-034626","form_type":"8-K/A","ticker":null,"cik":"0001496323","company_name":"IGM Biosciences, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.780782+00:00","generated_at":"2026-05-25T05:49:22.768441+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IGM Biosciences estimates restructuring charges of $0.7M-$2.0M from 2025 headcount reduction","bullets":["Total restructuring charges estimated between $0.7M and $2.0M.","Cash expenditures for severance and termination: $4.1M to $5.4M, offset by non-cash stock compensation credit of $3.4M.","Substantially all charges expected to be recognized in Q1 2025.","Follows Jan 10 announcement halting imvotamab and IGM-2644 development and reducing workforce by ~73%.","Estimates subject to assumptions; actual costs may differ materially."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-034626","json":"https://secwatch.observer/filing/0000950170-25-034626.json","markdown":"https://secwatch.observer/filing/0000950170-25-034626.md","text":"https://secwatch.observer/filing/0000950170-25-034626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496323/000095017025034626/0000950170-25-034626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496323/000095017025034626/igms-20250107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T05:49:22.768441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f443813b4daad605f609ec2350f33676f71c99e8","claim":"IGM Biosciences, Inc. announced a restructuring with charges of between $0.7 million and $2.0 million.","evidence_excerpt":"As a result of the 2025 Restructuring, the Company estimates it will incur total restructuring charges between $0.7 million and $2.0 million, consisting of cash expenditures between $4.1 million and $5.4 million for severance and one-time termination costs offset by non-cash compensation and stock-based compensation expense credit of $3.4 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496323/000095017025034626/0000950170-25-034626-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"between $0.7 million and $2.0 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}